Loading organizations...
Key people at ActiveSite.
ActiveSite Pharmaceuticals is a Berkeley, California-based biotechnology company that discovers and develops small-molecule therapeutics targeting disease-relevant enzymes and proteins. The firm primarily focuses its research and development efforts on creating novel protease inhibitors to treat severe neurodegenerative conditions, specifically Alzheimer's Disease and Parkinson's Disease. Operating within the competitive pharmaceutical drug discovery sector, the organization has historically funded its clinical pipeline through venture capital, research grants, and strategic partnerships, including a notable development and license agreement with AntriaBio, Inc. Although the enterprise established a specialized approach to protease biology and protein modification, public records indicate the corporate entity may have become inactive following its deregistration in the state of California. ActiveSite Pharmaceuticals was founded in 2006 by Sukanto Sinha and Tamie Chilcote, who brought over forty-eight combined years of pharmaceutical industry experience to the venture.
Key people at ActiveSite.
ActiveSite Pharmaceuticals, Inc. is a biopharmaceutical company developing small molecule drugs targeting proteases for diseases in the nervous system, cardiovascular, and eye domains, with a preclinical pipeline focused on conditions like ischemic stroke, diabetic macular edema, and macular edema.[2][3] It serves patients and healthcare providers by addressing unmet needs in these areas through proprietary lead discovery technology that identifies novel protease inhibitors, currently advancing candidates such as ASP-PDC-010, ASP-PDC-030, ASP-PDC-020, and RZ-402, all at the preclinical stage as of late 2025.[3]
The company demonstrates early research momentum via partnerships, including a license and development agreement with AntriaBio for plasma kallikrein inhibitors and another development and license deal documented in SEC filings, highlighting its strategy to monetize intellectual property while progressing its protease-focused platform.[4][5]
ActiveSite Pharmaceuticals emerged from expertise in protease-targeted drug discovery, utilizing proprietary technology to identify small molecule candidates for challenging therapeutic areas like nervous system diseases.[2][4] Key figures associated with the company include scientists such as Edward P. Feener, Tamie J. Chilcote, Sukanto Sinha, Allen C. Clermont, Sven-Erik Bursell, and Joanna A. Phipps, who contribute to its focus on cardiovascular, eye, and neurological disorders.[2]
Pivotal early moments include licensing deals, such as the agreement with AntriaBio announced for plasma kallikrein inhibitors, leveraging ActiveSite's IP platform, and a formal development and license pact noted in 2017 SEC documents, which validated its technology and supported pipeline progression.[4][5] These steps mark its evolution from discovery-focused biotech to one pursuing clinical translation.
ActiveSite rides the wave of precision protease inhibition in biotech, a trend gaining traction amid advances in understanding protease roles in neurodegeneration, vascular damage, and retinal disorders, amplified by AI-driven drug discovery tools as of 2025.[2][3] Timing aligns with rising demand for small molecule therapies in CNS and ophthalmology, where biologics face delivery challenges, and market forces like aging populations boost needs for stroke and macular edema treatments.
By licensing IP to partners like AntriaBio, ActiveSite influences the ecosystem through technology transfer, accelerating industry-wide development of kallikrein and related inhibitors while conserving resources for its core pipeline.[4] This positions it as an enabler in the preclinical biotech segment, contributing to broader efforts in orphan and high-burden diseases.
ActiveSite's next milestones likely involve advancing its preclinical assets—ASP-PDC-010 for diabetic macular edema, ASP-PDC-030 for ischemic stroke, and others—toward IND-enabling studies, potentially via additional partnerships to fund Phase 1 entry.[3] Trends like AI-enhanced protease modeling and combo therapies for neurovascular diseases will shape its path, with small molecules offering advantages in blood-brain barrier penetration.
Its influence may grow through expanded licensing, evolving from pure discovery to a platform licensor, mirroring successful biotechs that thrive on IP without full clinical risk, ultimately delivering targeted therapies to underserved patients.
